Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer

Lorenzo Belluominia Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, ItalyView further author information

Alice Avancinia Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy;b Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, ItalyView further author information

Marco Spositoa Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, ItalyView further author information

Michele Milellaa Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, ItalyView further author information

Antonio Rossic Oncology Centre of Excellence, Therapeutic Science & Strategy Unit, Milan, ItalyCorrespondence[email protected]
View further author information

Sara Pilottoa Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, ItalyView further author information

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date